PCC1™ Procyanidin Blend
A universal senolytic procyanidin blend with procyanidin C1 as the primary active component. Pharmaceutical-grade manufacturing for longevity research protocols and cellular senescence studies.
What is PCC1™?
Understanding cellular senescence and the universal senolytic approach
As we age, damaged cells accumulate in our tissues—cells that should naturally clear themselves but instead linger like "zombie cells." These senescent cells don't divide, but they don't die either. Instead, they release inflammatory signals that accelerate aging across multiple organ systems.
PCC1™ is a standardized procyanidin blend—not pure procyanidin C1, but a natural extract where procyanidin C1 is the primary active component. This blend selectively identifies and removes zombie cells from your body, allowing healthy tissue to regenerate. Unlike other senolytics that only work in specific tissues, PCC1™ demonstrates activity across kidneys, liver, lungs, and blood—making it a universal senolytic.
Derived from plant sources (grape seed extract), PCC1™ contains a spectrum of procyanidins with procyanidin C1 as the key senolytic molecule. This represents a breakthrough in senolytic research for its broad-spectrum tissue activity and favorable safety profile in preclinical models.
Natural Sources of Procyanidin
Rich in oligomeric procyanidins
Mediterranean polyphenols
Cocoa-derived procyanidins
Polyphenol-rich catechins
199 Labs uses pharmaceutical-grade extraction to produce a standardized procyanidin blend
with procyanidin C1 as the primary active component (not pure procyanidin C1).
Research Use Product
PCC1™ is intended for research applications, longevity protocols, and cellular senescence studies. This product is not intended to diagnose, treat, cure, or prevent any disease.
How PCC1™ Works
The upstream mechanism behind universal senolytic activity
Your body has a natural "cleanup crew"—proteins called PUMA and NOXA that tell damaged cells to self-destruct. But as we age, senescent cells develop sophisticated "survival shields" that block this cleanup signal.
The procyanidins in PCC1™—particularly procyanidin C1, the primary active component—work upstream, reactivating PUMA and NOXA to overwhelm these shields. Think of it as restoring your body's original instructions: damaged cells receive the signal, healthy cells are spared, and your tissues can regenerate.
Detection
PCC1™ identifies cells with senescent markers across multiple tissue types
Activation
Upregulates PUMA/NOXA proteins—your body's natural "self-destruct" signal
Clearance
Senescent cells undergo apoptosis; healthy cells remain unaffected
What Makes This Universal?
Most senolytics work in one tissue type (e.g., only fat cells or only skin). PCC1™'s procyanidin blend—with procyanidin C1 as the primary active component—works across organs because it activates upstream pathways common to all senescent cells.
In preclinical models, this resulted in clearance from kidneys, liver, lungs, and blood—supporting whole-body applications in longevity research protocols.
The Science Behind PCC1™
Research data supporting PCC1™'s universal senolytic activity
Human Pilot Data
A pilot study conducted by 199 Biotechnologies measured senescence markers in blood cells from 17 participants (ages 50-86). After just 3 days of PCC1™ administration, participants showed:
- 13-73% reduction in p16INK4a (validated senescence marker in T-cells)
- 30-70% reduction in SASP factors (IL-6, TGF-β1, VEGF, IL-8)
- 3-day protocol demonstrating rapid senescence marker modulation
While blood markers don't directly measure organ-level senescence, they provide promising early evidence of PCC1's activity in human subjects.
Multi-Tissue Activity
Preclinical research demonstrated senescent cell clearance across diverse tissue types:
Reduced p16+ cells
Senescence burden
Function markers
Cell populations
Vascular health
Neural tissue
Dermal layers
Muscle & bone
Hormonal systems
Eye tissue
Adipose tissue
The Upstream Mechanism Advantage
PCC1's procyanidin blend—particularly the procyanidin C1 component—functions as a PUMA/NOXA-centric senotherapeutic. It upregulates BH3-only proteins upstream of the apoptotic cascade, bypassing cell-type-specific senescent cell anti-apoptotic pathways (SCAPs).
This upstream activation explains PCC1's demonstrated efficacy across dermal fibroblasts, hematopoietic stem cells, adipose progenitors, and organ tissues in preclinical research models.
Why Choose 199 Labs' PCC1?
Pharmaceutical-grade manufacturing meets longevity research expertise
Manufacturing Excellence
HPLC-verified with procyanidin C1 as primary component
London & Shenzhen research labs
Quality management systems certified
Heavy metals, contaminants, and potency verified
Multiple Formats Available: Capsules and powder options for flexible research applications and custom protocols.
Research Leadership
199 Labs is the manufacturing division of 199 Biotechnologies—a UK-based longevity research company. We don't just manufacture senolytics; we conduct the research that identifies next-generation compounds.
Founder, 199 Biotechnologies
Longevity research & senolytic development
Chief Technology Officer
Tsinghua University, Cellular senescence research
Lonvi Labs Collaboration: Partnership with leading longevity research institutions for clinical implementation and protocol development.
Transparent Science
We publish our research, acknowledge limitations, and prioritize mechanistic rigor over marketing claims. From research bench to manufacturing facility—integrity at every step.
Frequently Asked Questions
Common questions about PCC1 and senolytic research
What are senescent cells?
Senescent cells—often called "zombie cells"—are damaged cells that should naturally clear themselves but instead accumulate with age. They don't divide or die, but they release inflammatory signals (SASP factors) that damage surrounding tissues. Clearing these cells is a promising strategy for addressing age-related tissue dysfunction.
How is PCC1 different from other senolytics?
Most senolytics are tissue-specific (e.g., BCL-XL inhibitors work primarily in fat cells and platelets). PCC1 works upstream by activating PUMA/NOXA pathways common to all senescent cells, resulting in multi-tissue activity:
- PCC1: Universal activity across kidneys, liver, lungs, blood
- Dasatinib + Quercetin (D+Q): Limited tissue penetration
- Fisetin: Requires very high doses for senolytic effect
What does the research show?
Human pilot data from 199 Biotechnologies (n=17, ages 50-86) demonstrated 13-73% reductions in senescence markers (p16INK4a) after 3-day administration. Preclinical models showed multi-tissue senescent cell clearance and favorable safety profiles.
Note: This is preliminary research data. PCC1 is intended for research use, not for disease treatment or prevention.
Who uses PCC1?
PCC1 is used by longevity clinics, research institutions, and individuals following advanced longevity protocols. Common applications include cellular senescence research, hit-and-run senolytic protocols, and biomarker-guided longevity optimization.
Is PCC1 pure procyanidin C1?
No. PCC1 is a standardized procyanidin blend—a grape seed extract containing multiple procyanidins with procyanidin C1 as the primary active component. This is not isolated/pure procyanidin C1.
The blend approach mirrors natural plant composition while ensuring consistent senolytic activity through standardized procyanidin C1 content. Research data reflects this blend formulation, not pure procyanidin C1.
What formats are available?
199 Labs offers PCC1 in multiple formats to accommodate different research needs: capsules for convenient protocols and powder for custom formulations. Bulk quantities available for institutional research and longevity clinic partnerships.
Is PCC1 safe?
Preclinical models demonstrate favorable safety profiles with PCC1 administration. Human pilot data showed good tolerability in a 3-day protocol.
Important: PCC1 is a research product, not a dietary supplement. Consult qualified healthcare practitioners before implementing senolytic protocols. This product is not intended to diagnose, treat, cure, or prevent any disease.
How do I implement PCC1 protocols?
Research protocols typically follow a "hit-and-run" approach (3 days on, 28 days off) to minimize prolonged senolytic exposure. Biomarker tracking (p16INK4a, SASP factors) can help assess individual responses.
199 Labs partners with longevity clinics and provides technical consultation for research institutions implementing senolytic protocols. Contact us for protocol guidance and biomarker recommendations.
Questions about PCC1 research protocols? Our team is here to help.